An UpToDate review on "Screening for prostate cancer" (Hoffman, 2018) recommend prostate cancer screening beginning at age 40 to 45 years for men at high risk (e.g., black men, men with family history of prostate cancer, particularly in relatives younger than age 65, and men who are know...
Currently, most prostate cancer treatment guidelines worldwide recommend an observation-based approach, primarily active surveillance, for such cases, resembling a treatment model for precancerous conditions rather than curative treatment for the majority of cancers26,27. In the 12 cases with a PI-...
Nearly one-third of patients with prostate cancer (PCa) experience biochemical recurrence (BCR) after primary definitive treatment. BCR increases the risk of distant metastasis and mortality in patients with prognostically unfavorable features. These patients are best managed with a tailored treatment str...
Rockville, MD: Agency for Healthcare Research and Quality; 2018. AHRQ publication 17-05229-EF-3. 25. Wolters T, Roobol MJ, Steyerberg EW, et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer. 2010;126(10):2387-2393.PubMed...
The CACA Guidelines for Holistic Integrative Management of Prostate Cancer includes epidemiology, screening and diagnosis, treatment for localized PC, diagnosis and treatment of PC recurrence after radical prostatectomy, management of metastatic PC, traditional Chinese medicine diagnosis and treatment of PC,...
Less health education about treatment choices Lower quality care Less high-benefit treatments, such as surgery Bad advice.From 2012 to 2018, the U.S. Preventive Services Task Force (USPSTF) said they didn’t think the PSA test should be used for routine prostate cancer screening. That’s a ...
Bladder filling variation during radiation treatment of prostate cancer: can the use of a bladder ultrasound scanner and biofeedback optimize bladder filling? Int J Radiat Oncol Biol Phys. 2006;65(2):371–7. Article Google Scholar O’Doherty UM, McNair HA, Norman AR, Miles E, Hooper S, ...
Table 1. Ongoing clinical trials with radionuclides for the treatment of prostate cancers (source: clinicaltrials.gov; last accession 15 November 2022). PCa: prostate cancer; BCR: biochemical recurrent; mHSPC: metastatic hormone sensitive prostate cancer; mCRPC: metastatic-castration resistant prostate ...
prostate cancer; aptamers; Prostate-Specific Membrane Antigen (PSMA); Prostate-Specific Antigen (PSA); PCa diagnosis; PCa treatment1. Introduction For decades, the efforts to understand and cure diseases have been a challenge in medicine. Although many drugs have been developed to treat specific ...
Local treatment for metastatic prostate cancer: a systematic review. Int J Urol. 2018;25(5):390-403.Tilki D, Pompe RS, Bandini M, Marchioni M, Kretschmer A, Tian Z, Karakiewicz PI, Evans CP. Local treatment for metastatic prostate cancer: a systematic review. Int J Urol. 2018;25:390...